Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713084 | 1.00 | CYP4F2 (0.33) | CYP4F2CYP4A11KDM4EMEN1ALDH1A1 | |
| SCHEMBL14295197 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL4566681 | 0.85 | CYP4F2 (0.35) | CYP4F2CYP4A11KDM4EMEN1ALDH1A1 | |
| SCHEMBL22098331 | 0.79 | CYP4F2 (0.36) | CYP4F2CYP4A11KDM4EMEN1ALDH1A1 | |
| SCHEMBL13744664 | 0.79 | CYP4F2 (0.36) | CYP4F2CYP4A11KDM4EMEN1ALDH1A1 | |
| SCHEMBL15867020 | 0.78 | ALDH1A1 (0.47) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL14500716 | 0.77 | CYP4F2 (0.33) | CYP4F2CYP4A11KDM4EMEN1ALDH1A1 | |
| SCHEMBL762461 | 0.76 | ALDH1A1 (0.50) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL16368849 | 0.74 | HTR2A (0.38) | MEN1ALDH1A1KMT2A | |
| SCHEMBL12548932 | 0.74 | CYP4F2 (0.39) | CYP4F2CYP4A11KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| EP-1323710-B1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-09-10 | — | — | EP | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7138397-B2 | Nitrogenous 5-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2006-11-21 | — | — | US | disclosed |
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1323710-A1 | NITROGENOUS FIVE-MEMBERED RING COMPOUNDS | Tanabe Seiyaku Co., Ltd. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241146-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | CYP4F2 1497/4885CYP4A11 987/4885KDM4E 2108/4885 |
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | CYP4F2 1612/4885CYP4A11 742/4885KDM4E 2657/4885 |
| US-20050054678-A1 | Nitrogenous five-membered ring compounds | ALK, NPR1, SCO2 | CYP4F2 1024/4885CYP4A11 853/4885KDM4E 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.